Related coverage linked through entity extraction aliases.
May 13, 2026
Tumour-infiltrating lymphocyte therapy has shown durable responses in refractory melanoma, including a 31.4% objective response rate in phase II data. The 2024 FDA approval of Lifileucel marked a milestone as regulators in other markets continue reviews.
Apr 21, 2026
TMEM87A was identified as a mediator of ferroptosis resistance through buffering Golgi pH. In murine tumor models, TMEM87A ablation suppressed tumor progression and potentiated PD1 blockade therapy.
Mar 12, 2026
Study finds advanced melanoma patients with sufficient vitamin D levels showed better response rates and longer survival when receiving anti-PD-1 immunotherapy compared to those with low vitamin D status.
Mar 11, 2026
Recent studies demonstrate PD-1 antibody combinations improve survival in natural killer/T-cell lymphoma and show activity in previously treated advanced non-small cell lung cancer, with manageable safety profiles across treatment settings.
Mar 09, 2026
A study published in Nature Microbiology demonstrates that a defined consortium of 15 gut bacterial species derived from immunotherapy responders significantly enhances anti-PD-1 treatment efficacy in mouse models of non-small-cell lung cancer.
Feb 16, 2026
CStone Pharmaceuticals has received FDA clearance for its IND application to initiate a Phase II trial of CS2009, a trispecific antibody targeting PD-1, VEGFA, and CTLA-4, in patients with advanced solid tumors across nine cancer indications.
